Contraindications to GLP-1 therapy, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, are reviewed at this stage per FDA prescribing guidelines [3]
This might include changing your injection schedule, modifying your nutritional plan, or incorporating specific supplements to support your metabolic health, including the Weight Loss Boost supplement
Federal regulators have also begun to increase enforcement actions against companies promoting compounded GLP-1 drugs with misleading claims about safety and equivalence to approved medicines
Ready to explore whats possible
These actions include, but are not limited to, seizure, injunction, and civil money penalties." The agency also noted that Quality System regulation violations "reasonably related to premarket approval applications for Class III devices" could prevent device approvals, and "requests for Certificates to Foreign Governments (CFG) may not be granted." Quality management system transition FDA reminded Zoll that while the inspection was conducted under the Quality System Regulation in effect at the time, any corrective actions proposed or implemented must be pursuant to the QMSR requirements in effect as of February 2, 2026, referring to the newly implemented Quality Management System Regulation
.png)
